Endometriosis Management: Hormonal Therapy and Surgical Decision-Making
Diagnosis: Clinical Suspicion and Imaging
Endometriosis should be suspected in any woman with cyclic or chronic pelvic pain, dysmenorrhea unresponsive to NSAIDs, dyspareunia, or subfertility. Transvaginal ultrasound (TVUS) with expert sonography detects endometriomas with sensitivity of 93% and deep infiltrating endometriosis (DIE) with sensitivity of 79-94% using the International Deep Endometriosis Analysis (IDEA) group standardized approach. MRI provides complementary information for retrocervical, uterosacral, and bowel endometriosis (sensitivity 90%, specificity 91%). Laparoscopy is no longer required for diagnosis per the ESHRE 2022 guideline update; empiric treatment based on clinical suspicion and imaging is now recommended as first-line.
First-Line Hormonal Therapy
Combined oral contraceptives (continuous regimen preferred) reduce dysmenorrhea in approximately 60-80% of patients and are recommended as first-line medical therapy. Progestins represent the primary evidence-based alternative: dienogest 2 mg daily demonstrated a 5-point reduction on the VAS pain scale (from 6.4 to 1.5) at 24 weeks in the pivotal phase 3 trial. Norethindrone acetate 5 mg daily and the levonorgestrel IUD (52 mg) are effective alternatives with different side effect profiles. The levonorgestrel IUD reduces endometriosis-associated pain with a mean VAS reduction of 4.2 points at 6 months, with the added advantage of contraception and fewer systemic progestogenic side effects.
Second-Line Medical Therapy: GnRH Antagonists
Oral GnRH antagonists have transformed second-line endometriosis management. Elagolix (150 mg daily for non-menstrual pain, 200 mg twice daily for dysmenorrhea) reduced dysmenorrhea by 46-76% versus placebo in the ELARIS EM-I/II trials. Relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg daily) provides estrogen add-back within the same tablet, maintaining BMD while achieving pain reduction comparable to GnRH agonist depot injections. The SPIRIT trials demonstrated that 24 weeks of relugolix CT reduced dysmenorrhea VAS scores by 63% versus 28% for placebo, with less than 1% mean BMD loss at the lumbar spine.
Sponsored
Surgical Decision-Making: When and How
Surgery is indicated for refractory pain after adequate medical therapy (typically 3-6 months), large endometriomas (above 4 cm or symptomatic), bowel or ureteral obstruction, and infertility with associated endometriomas. Laparoscopic excision is preferred over ablation for deep infiltrating endometriosis based on the randomized trial by Healey et al. showing lower pain recurrence at 5 years (27% versus 57%, p=0.004). For endometriomas, the ESHRE guidelines recommend cystectomy over drainage and ablation for improved fertility outcomes (spontaneous pregnancy rate 54% versus 23% at 12 months in the Cochrane meta-analysis).
Endometriosis and Fertility
Endometriosis is identified in 25-50% of infertile women. The EFI (Endometriosis Fertility Index) score at surgery predicts non-IVF pregnancy rates and guides post-surgical management. For mild-moderate disease (rASRM stage I-II), the Canadian ENDOCAN trial showed controlled ovarian stimulation plus IUI increased pregnancy rates from 4% to 15% per cycle versus expectant management. For moderate-severe disease or after failed conservative surgery, IVF achieves live birth rates of 40-50% per cycle, comparable to non-endometriosis IVF outcomes. Prolonged GnRH agonist suppression (2-3 months) before IVF improves live birth rates by an OR of 4.28 (95% CI 2.00-9.15) per the Cochrane analysis.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.